Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection

被引:198
作者
Hu, Mary Y. [1 ]
Katchar, Kianoosh [1 ]
Kyne, Lorraine [2 ]
Maroo, Seema [1 ]
Tummala, Sanjeev [1 ]
Dreisbach, Valley [1 ]
Xu, Hua [1 ]
Leffler, Daniel A. [1 ]
Kelly, Ciaran P. [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol,Dept Med, Boston, MA 02215 USA
[2] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Dept Med Older Person, Dublin 2, Ireland
基金
美国国家卫生研究院;
关键词
INTRAVENOUS IMMUNOGLOBULIN; PSEUDOMEMBRANOUS COLITIS; SACCHAROMYCES-BOULARDII; ANTIBODY-RESPONSE; TOXIN-A; RISK-FACTORS; DIARRHEA; DISEASE; VANCOMYCIN; SEVERITY;
D O I
10.1053/j.gastro.2008.12.038
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Prevention of recurrent Clostridium difficile infection (CDI) is a substantial therapeutic challenge. A previous prospective study of 63 patients with CDI identified risk factors associated with recurrence. This study aimed to develop a prediction rule for recurrent CDI using the above derivation cohort and prospectively evaluate the performance of this rule in an independent validation cohort. Methods: The clinical prediction rule was developed by multivariate logistic regression analysis and included the following variables: age >65 years, severe or fulminant illness (by the Horn index), and additional antibiotic use after CDI therapy. A second rule combined data on serum concentrations of immunoglobulin G (IgG) against toxin A with the clinical predictors. Both rules were then evaluated prospectively in an independent cohort of 89 patients with CDI. Results: The clinical prediction rule discriminated between patients with and without recurrent CDI, with an area under the curve of the receiver-operating-characteristic curve of 0.83 (95% confidence interval [CI]: 0.70-0.95) in the derivation cohort and 0.80 (95% Cl: 0.67-0.92) in the validation cohort. The rule correctly classified 77.3% (95% CI: 62.2%-88.5%) and 71.9% (95% CI: 59.2%-82.4%) of patients in the derivation and validation cohorts, respectively. The combined rule performed well in the derivation cohort but not in the validation cohort (area under the curve of the receiver-operating-characteristic curve, 0.89 vs 0.62; diagnostic accuracy, 93.8% vs 69.2%, respectively). Conclusions: We prospectively derived and validated a clinical prediction rule for recurrent CDI that is si le, reliable, and accurate and can be used to identify high-risk patients most likely to benefit from measures to prevent recurrence.
引用
收藏
页码:1206 / 1214
页数:9
相关论文
共 42 条
[1]   SERUM ANTIBODY-RESPONSE TO CLOSTRIDIUM DIFFICILE TOXINS IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DIARRHEA [J].
ARONSSON, B ;
GRANSTROM, M ;
MOLLBY, R ;
NORD, CE .
INFECTION, 1985, 13 (03) :97-101
[2]   Treatment of Clostridium difficile-associated disease:: old therapies and new strategies [J].
Aslam, S ;
Hamill, R ;
Musher, DM .
LANCET INFECTIOUS DISEASES, 2005, 5 (09) :549-557
[3]   IMMUNOGLOBULIN-G DIRECTED AGAINST TOXIN-A AND TOXIN-B OF CLOSTRIDIUM-DIFFICILE IN THE GENERAL-POPULATION AND PATIENTS WITH ANTIBIOTIC-ASSOCIATED DIARRHEA [J].
BACON, AE ;
FEKETY, R .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 18 (04) :205-209
[4]   ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS DUE TO TOXIN-PRODUCING CLOSTRIDIA [J].
BARTLETT, JG ;
CHANG, TW ;
GURWITH, M ;
GORBACH, SL ;
ONDERDONK, AB .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (10) :531-534
[5]   Narrative review: The new epidemic of clostridium difficile-associated enteric disease [J].
Bartlett, John G. .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (10) :758-764
[6]   ASSESSING ILLNESS SEVERITY - DOES CLINICAL JUDGMENT WORK [J].
CHARLSON, ME ;
SAX, FL ;
MACKENZIE, CR ;
FIELDS, SD ;
BRAHAM, RL ;
DOUGLAS, RG .
JOURNAL OF CHRONIC DISEASES, 1986, 39 (06) :439-452
[7]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[8]   Risk factors for early recurrent Clostridium difficile -: Associated diarrhea [J].
Do, AN ;
Fridkin, SK ;
Yechouron, A ;
Banerjee, SN ;
Killgore, GE ;
Bourgault, AM ;
Jolivet, M ;
Jarvis, WR .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :954-959
[9]  
Fekety R, 1997, AM J GASTROENTEROL, V92, P739
[10]   Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial [J].
Fekety, R ;
McFarland, LV ;
Surawicz, CM ;
Greenberg, RN ;
Elmer, GW ;
Mulligan, ME .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (03) :324-333